Promising combo tackles rare lymphoma in early trial
NCT ID NCT04433156
First seen Apr 10, 2026 · Last updated May 20, 2026 · Updated 6 times
Summary
This study tested a combination of drugs called VR-CAP as a first treatment for people with marginal zone lymphoma, a rare blood cancer. 26 patients received the therapy to see how well it controlled the disease over two years. The goal was to measure how long patients lived without their cancer getting worse, while also tracking side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university
Zhengzhou, Henan, China
Conditions
Explore the condition pages connected to this study.